Trial Profile
Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Tamoxifen (Primary) ; Vorinostat (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jun 2020 Status changed from active, no longer recruiting to discontinued.
- 17 Jan 2019 Planned End Date changed from 1 Aug 2019 to 20 Dec 2021.
- 17 Jan 2019 Planned primary completion date changed from 1 Aug 2018 to 20 Dec 2019.